• Darling Ingredients, through its Rousselot health brand, recently received a U.S. patent for Nextida GC, a collagen peptide ingredient designed to support healthy after-meal blood sugar levels, covering both its production process and use as a dietary supplement.
• This patent underscores the company’s push into science-backed, collagen-based health ingredients, adding a differentiated, non-pharmaceutical option to its wider specialty nutrition portfolio.
• We’ll now consider how this newly patented collagen solution for blood sugar control could reshape Darling Ingredients’ investment narrative in health-focused ingredients.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Darling Ingredients Investment Narrative Recap

To own Darling Ingredients, you need to believe in its ability to turn waste and animal byproducts into higher value ingredients while managing policy and feedstock volatility in renewable fuels. The Nextida GC patent strengthens the health ingredients story, but it does not materially change the near term focus on improving renewable diesel utilization and managing leverage, which remain the most important catalyst and key risk for the stock right now.

The most relevant recent announcement alongside this patent is the planned Nextida collagen and gelatin joint venture with Tessenderlo Group, targeting about US$1.5 billion of initial revenue. Together, the JV and the new U.S. patent frame a clearer path for Darling’s collagen platform to move up the value chain into health focused ingredients, a potential counterbalance to volatility in renewable fuels if execution and market adoption play out over time.

Yet, despite these promising health ingredients developments, investors should still be aware of the risk that renewable fuel policy shifts could...

Darling Ingredients’ narrative projects $7.2 billion revenue and $676.3 million earnings by 2029.

Uncover how Darling Ingredients' forecasts yield a $72.17 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most pessimistic analysts saw more risk that new health products might struggle to gain traction, even while forecasting revenue around US$6.3 billion and earnings near US$519.5 million by 2028, so it is worth asking how a patented blood sugar collagen ingredient could shift that story.

Explore 3 other fair value estimates on Darling Ingredients - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Darling Ingredients research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Darling Ingredients research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Darling Ingredients' overall financial health at a glance.

No Opportunity In Darling Ingredients?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.